Qualigen Therapeutics, Inc. (AIXC)
NASDAQ: AIXC · Real-Time Price · USD
2.840
0.00 (0.00%)
Nov 19, 2025, 3:08 PM EST - Market open
Company Description
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer.
The company’s lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors.
It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors.
The company was founded in 1996 and is based in Carlsbad, California.
Qualigen Therapeutics, Inc.
| Country | United States |
| Founded | 1996 |
| Employees | 4 |
Contact Details
Address: 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 United States | |
| Phone | 760 452 8111 |
| Website | qlgntx.com |
Stock Details
| Ticker Symbol | AIXC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |